[posting]38686561[/posting]
UND noch ein Artikel, brandaktuell:Source: Beacon Equity
Market Watch for Labopharm Inc. Issued by Beacon Equity
DALLAS, Jan. 7, 2010 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring pharmaceutical company Labopharm Inc. (Nasdaq: DDSS). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at: http://www.beaconequity.com/i/DDSS
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Labopharm Inc. (DDSS) is a worldwide specialty pharmaceutical company engaged in the application of its advanced controlled-release technologies to existing marketed drugs. Its lead technology, Contramid(R), is designed to improve performance of presently available drugs through a time-release function. The Company's lead drug, Tramadol, is marketed as a moderate to severe pain reliever. Other drugs presently in FDA trials include DDS-04A (SARI) containing Trazodone Hydrochloride, DDS-06C containing Tramadol-Acetaminophen, DDS-06A containing Acetaminophen, DDS-06B containing Tramadol, DDS-07L and DDS-07U, DDS-04F (Propofol) and DDS-06E: SN-38 for the treatment of colon cancer.
In the report, the analyst notes:
"The Company's novel pain relief technologies are an innovative approach to anti-inflammation, which is estimated to address an approximate 400 million number of incidents of acute inflammation conditions each year. The market for anti-inflammation products is anticipated to grow beyond the current $10 billion market, worldwide.
"The Company's DDS-06E is under development for the treatment of colon cancer. According to the Cancer Market Outlook report published by Business Insights, the market for cancer therapeutic drugs is expected to reach $40.9 billion by 2012. If approved by the U.S. Food and Drug Administration (FDA), the market for the Company's drug candidates has a potential to reach more than $1 billion at market saturation."
To read the entire report visit: http://www.beaconequity.com/i/DDSS
See what investors are saying about DDSS at penny stock forum.
BeaconEquity.com is one of the industry's largest small-cap report providers striving to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
CONTACT: Beacon Equity Research
Jeff Bishop
(469)-252-3505
press@beaconequity.com